ORAGENICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ORAGENICS, INC. (OGEN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-16
- ORAGENICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.01M.
- ORAGENICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$1.41M.
- ORAGENICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$5.79M.
- ORAGENICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$3.71M, a 526.55% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.01M 10-K · filed 2026-03-16 | |
| 2024-12-31 | -$1.41M 10-K · filed 2026-03-16 | |
| 2023-12-31 | -$5.79M 10-K · filed 2025-03-14 | |
| 2022-12-31 | -$3.71M 10-K · filed 2024-03-29 | $3.71M 10-K · filed 2023-04-17 |
| 2021-12-31 | $870.94K 10-K · filed 2023-04-17 | |
| 2020-12-31 | $6.48M 10-K/A · filed 2022-07-29 | |
| 2019-12-31 | $3.87M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $2.49M 10-K · filed 2020-03-04 | |
| 2017-12-31 | -$10.06M 10-K · filed 2019-03-29 | $10.06M 10-K · filed 2018-02-16 |
| 2016-12-31 | $2.59M 10-K · filed 2018-02-16 | |
| 2015-12-31 | $4.27M 10-K · filed 2017-02-27 | |
| 2014-12-31 | $2.05M 10-K · filed 2016-03-30 | -$2.05M 10-K · filed 2015-02-27 |
| 2013-12-31 | -$5.68M 10-K · filed 2015-02-27 | |
| 2012-12-31 | -$4.88M 10-K · filed 2014-02-28 | $4.88M 10-K · filed 2013-03-26 |
| 2011-12-31 | $2.55M 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |